|
Company Name:
|
Noxopharm Limited (ABN 50 608 966 123)
|
|
Business Description:
|
Noxopharm Limited (ASX: NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation, as well as improving mRNA vaccines.
|
|
Established:
|
Noxopharm Limited (NOX) was listed on the Australian Securities Exchange on 9 August 2016
Noxopharm Pty Ltd was incorporated in October 2015.
|
|
Listings:
|
Australian Securities Exchange (ASX: NOX)
|
|
Shares on Issue:
|
~ 292,237,950 ordinary shares
|
|
Board of Directors:
|
Dr Gisela Mautner (CEO and Managing Director)
Mr Fred Bart (Non-Executive Chair)
Mr Peter Marks (Non-Executive Director and Deputy Chairman)
Mr Boris Patkin (Non-Executive Director)
|
|
Company Secretary:
|
Mr David Franks
|
|
Chief Financial Officer:
|
Mr Shawn van Boheemen
|
|
Share Registry:
|
Automic Registry Services
Level 5, 126 Phillip Street, Sydney, NSW, Australia, 2000
|
|
Telephone:
|
1300 288 664 (within Australia)
+61 2 9698 5414 (outside Australia)
|
|
Registered Office:
|
Level 5, 126 Phillip Street, Sydney, NSW 2000
|
|
Postal:
|
Suite 71, 159 Ridgecrop Drive, Castle Hill, NSW 2154
|
|
Auditors:
|
William Buck
|
